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Case report
A 26-year-old female patient underwent kidney trans-
plantation from a 38-year-old deceased donor in 2001.
Her renal disease was a focal segmental hyalinosis
secondary to congenital vesico-ureteral reflux. She was
started on triple immunosuppressive therapy [tacro-
limus, mycophenolate mofetil (MPM) and prednisone].
Renal transplantation was complicated by delayed
graft function and a renal biopsy was performed on the
day 8, showing histological signs of tubular necrosis
without acute rejection. Thereafter, evolution was
excellent and corticosteroids were stopped after
1 year. Creatinine at 1 year was 100 mmol/l. She had
arterial hypertension which was treated with four
antihypertensive drugs just after renal transplantation;
the treatment was progressively decreased and
18 months after transplantation, she required no
further antihypertensive therapy. A routine renal
biopsy was performed after steroid withdrawal in
2002, showing no evidence of rejection but a moderate
interstitial fibrosis (10–20%). Tacrolimus and MPM
were continued and trough levels of tacrolimus were
aimed for 6–8 mg/l. All follow-up visits between 2002
and 2005 were unremarkable, except one respiratory
infection which was treated with antibiotics for 7 days.
Renal function was extremely stable with values
averaging 100 mmol/l (83–114 mmol/l) of creatinine
during these 3 years (Figure 1). She had no proteinuria
(170mg/day). Tacrolimus trough level was kept
between 6 and 8 mg/l with 1.5mg b.i.d. During this
period, she was also taking an oral contraception
(estradiol and progesterone), magnesium and para-
cetamol for common migraines. She did not smoke or
drink alcohol.
During the summer of 2005 her common migraines
became exacerbated, no longer relieved by paraceta-
mol. In September 2005, her general practitioner
prescribed zolmitriptan 2.5mg to good effect. She
used this medication 3–4 times a month. In October
2005 she had a slight increase of creatinine at
120 mmol/l, but no other changes which might have
raised any concerns for her renal function; a control in
January was stable at 115 mmol/l. Due to an increase in
her headaches, she took zolmitriptan more frequently
during the following 2 months, reporting an average
consumption of 10 pills per week (Figure 1). She did
not complain of abdominal pains. In March 2006,
a control showed a creatinine value at 161 mmol/l
associated with an increase in proteinuria (500mg/day)
(Figure 1). There was no clinical explanation for this
rise, but tacrolimus trough levels were at the upper
limit of the target (8 mg/l) during the last 4 months
under the same drug regimen (1.5mg b.i.d). A renal
biopsy was performed. Several cortical ischaemic scars
were observed with globally sclerotic glomeruli and
arteriosclerosis (Figure 2A). The cortical region with-
out scars included eight glomeruli, four of them
globally sclerosed. Two glomeruli showed severe
ischaemic injury with corrugation of the basement
membranes (Figure 2B). In the two other glomeruli,
lesions of focal and segmental sclerosis were observed.
Some intratubular calcifications were detected.
Arterioles appeared unremarkable. A 99m-Tc-DMSA
renal scintigraphy was done, which did not reveal renal
defects compatible with large scars. Zolmitriptan and
tacrolimus were suspected to be involved in this acute
decline in renal function. Zolmitriptan was stopped
and tacrolimus dosage was slightly decreased, to 1mg
in the morning and 0.5mg in the evening. Creatinine
slowly decreased to 141 umol/l and a renal biopsy was
performed again in June 2006. The histology showed
the same cortical scars, and moderate arteriolar lesions
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that were compatible with calcineurin inhibitors
toxicity. The cortical region without scars included
12 glomeruli, six of which were globally sclerosed.
Six glomeruli showed open capillary loops and thin
basement membranes. Renal function continued
to improve and since October 2006, she has returned
to her usual creatinine values of 100 mmol/l.
Discussion
This young patient had a transient decline in the
function of her renal graft, associated with severely
ischaemic glomeruli and cortical scars on the renal
biopsy, which were attributed to ischaemic injuries
secondary to the introduction of zolmitriptan.
Zolmitriptan is a 5HT1 receptor agonist which is
very efficient in reversing the abnormal cerebral
vasodilatation associated with common migraine. As
with the other triptans, it acts through agonism at the
HT1D/B receptor subtype, a G-protein-coupled recep-
tor [1]. Its vasoconstrictor activity is mediated with the
vascular smooth muscle 5HT1b receptor subtype. This
receptor is described in human coronary, cerebral and
peripheral artery [2]. In young healthy and in elderly
subjects, administration of zolmitriptan increased
mean peak diastolic pressure from 6 to 10mmHg.
In addition, in the elderly, mean peak systolic blood
pressure values were 9–16mmHg higher after zolmi-
triptan than after placebo [3]. The vasoconstrictive
properties of the ‘triptans’ have been incriminated in
rare complications such as cerebro-vascular accident,
myocardial infarction, ischaemic colitis, spinal cord
infarction and renal infarction [4–7]. Renal arterial
vasospasm was shown to be 5-HT mediated in a rat [8]
and produces contractions and increased tone in the
renal artery in the rabbit [9]. 5HT1B receptor has not
been yet described in human renal artery, but a recent
case report suggests its presence [5]. Indeed, one case of
renal infarction was reported in a 34-year-old man
after one dose of 2.5mg of zolmitriptan [5]. This
case report demonstrates that renal graft can also
be exposed to ischaemic injuries secondary to the
vasoconstrictive properties of zolmitriptan.
Of importance, this patient was also under tacroli-
mus therapy, which may have enhanced the ischaemic
injuries induced by zolmitriptan. The calcineurin
inhibitors cyclosporine and tacrolimus are known
to elicit vasoconstriction in different vascular beds
[10]. Acute nephrotoxicity secondary to vasoconstric-
tion is well described with tacrolimus. The incidence
of headache as an adverse event is higher among
tacrolimus-treated patients than in cyclosporine-
treated patients [11]. There is a recent case report of a
transient ischaemic attack after rizatriptan administra-
tion in a liver transplant recipient, who developed
migraine while on tacrolimus therapy, suggesting that
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Fig. 2. (A) This is renal biopsy specimens obtained from the patient
on both tacrolimus and zolmitriptan. On light microscopy, ischaemic
cortical scar with obsolescent glomeruli, interstitial fibrosis, tubular
atrophy and arteriosclerosis are observed on this specimen (PAS,
50). (B) This is renal biopsy specimens obtained from the patient
on both tacrolimus and zolmitriptan. At higher magnification,
ischaemic injury is characterized by corrugation of the glomerular
basement membranes and retraction of the glomerular tuft
(PAS, 200).
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Fig. 1. Creatinine and tacrolimus (FK 506) values since the
beginning of the renal transplantation. Increase of creatinine
paralleles the exposure to zolmitriptan (cubes). The patient started
zolmitriptan in September 2005 with a moderate use of 3–4 pills per
month (small cube). In January 2006, she did increase zolmitriptan
doses to an average of 10 pills per week (large cube). When
zolmitriptan was stopped, creatinine came back slowly to previous
values.
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this association leads to an excessive risk of cerebral
vasospasm [4]. Several mechanisms are involved in the
vasoconstrictive action of tacrolimus. Among them,
endothelial cell dysfunction is a major mechanism,
including deficiency in NO-vasodilatory effect, increase
in peroxynitrite production and increase in endothelin
release [10]. In addition, adenosine, a renal vasocon-
strictor mediator, has been shown to be elevated by
tacrolimus administration [12]. However, it does not
seem that tacrolimus vasoconstrictive action is
mediated by 5-HT receptors. Thus, we suggest that
both drugs act synergistically to enhance vasoconstric-
tion in the renal graft, which might lead to severe
ischaemic lesions. The deleterious role of zolmitriptan is
further confirmed in this case report by the improve-
ment of renal function after its discontinuation,
whereas tacrolimus therapy was maintained. Thus, in
the presence migraines in a kidney recipient under
calcineurin inhibitors, agents specific for migraine, such
the various triptans, should be used with extreme
caution. Indeed, the combination of zolmitriptan or
other triptans and tacrolimus (or cyclosporine) can
increase the risk of acute or subacute ischaemic injuries
of the kidney graft and we advise strongly against it.
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